Literature DB >> 22467264

Delineating nuclear reprogramming.

Jolene Ooi1, Pentao Liu.   

Abstract

Nuclear reprogramming is described as a molecular switch, triggered by the conversion of one cell type to another. Several key experiments in the past century have provided insight into the field of nuclear reprogramming. Previously deemed impossible, this research area is now brimming with new findings and developments. In this review, we aim to give a historical perspective on how the notion of nuclear reprogramming was established, describing main experiments that were performed, including (1) somatic cell nuclear transfer, (2) exposure to cell extracts and cell fusion, and (3) transcription factor induced lineage switch. Ultimately, we focus on (4) transcription factor induced pluripotency, as initiated by a landmark discovery in 2006, where the process of converting somatic cells to a pluripotent state was narrowed down to four transcription factors. The conception that somatic cells possess the capacity to revert to an immature status brings about huge clinical implications including personalized therapy, drug screening and disease modeling. Although this technology has potential to revolutionize the medical field, it is still impeded by technical and biological obstacles. This review describes the effervescent changes in this field, addresses bottlenecks hindering its advancement and in conclusion, applies the latest findings to overcome these issues.

Mesh:

Substances:

Year:  2012        PMID: 22467264      PMCID: PMC4875473          DOI: 10.1007/s13238-012-2920-x

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  192 in total

1.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.

Authors:  C Bouchard; O Dittrich; A Kiermaier; K Dohmann; A Menkel; M Eilers; B Lüscher
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

2.  Oocyte-type linker histone B4 is required for transdifferentiation of somatic cells in vivo.

Authors:  Nobuyasu Maki; Rinako Suetsugu-Maki; Shozo Sano; Kenta Nakamura; Osamu Nishimura; Hiroshi Tarui; Katia Del Rio-Tsonis; Keita Ohsumi; Kiyokazu Agata; Panagiotis A Tsonis
Journal:  FASEB J       Date:  2010-05-11       Impact factor: 5.191

3.  Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice.

Authors:  Satoshi Nori; Yohei Okada; Akimasa Yasuda; Osahiko Tsuji; Yuichiro Takahashi; Yoshiomi Kobayashi; Kanehiro Fujiyoshi; Masato Koike; Yasuo Uchiyama; Eiji Ikeda; Yoshiaki Toyama; Shinya Yamanaka; Masaya Nakamura; Hideyuki Okano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

4.  Immunogenicity of induced pluripotent stem cells.

Authors:  Tongbiao Zhao; Zhen-Ning Zhang; Zhili Rong; Yang Xu
Journal:  Nature       Date:  2011-05-13       Impact factor: 49.962

5.  GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts.

Authors:  H Kulessa; J Frampton; T Graf
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

6.  Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells.

Authors:  Su-Yi Tsai; Carlos Clavel; Soo Kim; Yen-Sin Ang; Laura Grisanti; Dung-Fang Lee; Kevin Kelley; Michael Rendl
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

7.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

8.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells.

Authors:  Kosuke Yusa; S Tamir Rashid; Helene Strick-Marchand; Ignacio Varela; Pei-Qi Liu; David E Paschon; Elena Miranda; Adriana Ordóñez; Nicholas R F Hannan; Foad J Rouhani; Sylvie Darche; Graeme Alexander; Stefan J Marciniak; Noemi Fusaki; Mamoru Hasegawa; Michael C Holmes; James P Di Santo; David A Lomas; Allan Bradley; Ludovic Vallier
Journal:  Nature       Date:  2011-10-12       Impact factor: 49.962

9.  Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Authors:  Gabsang Lee; Eirini P Papapetrou; Hyesoo Kim; Stuart M Chambers; Mark J Tomishima; Christopher A Fasano; Yosif M Ganat; Jayanthi Menon; Fumiko Shimizu; Agnes Viale; Viviane Tabar; Michel Sadelain; Lorenz Studer
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

10.  Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2.

Authors:  Carlos F Pereira; Rémi Terranova; Natalie K Ryan; Joana Santos; Kelly J Morris; Wei Cui; Matthias Merkenschlager; Amanda G Fisher
Journal:  PLoS Genet       Date:  2008-09-05       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.